102
Participants
Start Date
December 15, 2020
Primary Completion Date
October 24, 2023
Study Completion Date
October 21, 2024
AeriSeal
The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.
Zephyr Valves
The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
University Hospital of Zurich, Zurich
Charité - Universitätsmedizin Berlin, Berlin
ASST Spedali Civili, University Hospital, Brescia
CHU Toulouse, Toulouse
Ruhrlandklinik Essen, Essen
ThoraxKlinik, Heidelberg
CHU Limoges, Limoges
The Wesley Hospital, Brisbane
Macquarie University Hospital, Sydney
University Medical Center Groningen, Groningen
Golden Jublilee National Hospital, Clydebank
University Hospital of Wales, Cardiff
Royal Brompton Hospital, London
Nottingham University Hospitals, Nottingham
Pulmonx Corporation
INDUSTRY